GSK 2696275

Drug Profile

GSK 2696275

Alternative Names: GSK2696275; WAS gene therapy - GlaxoSmithKline/Fondazione Telethon/Ospedale San Raffaele; WAS transduced autologous CD34+ stem cells - GlaxoSmithKline/Fondazione Telethon/Ospedale San Raffaele

Latest Information Update: 12 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fondazione Telethon; GlaxoSmithKline; Ospedale San Raffaele
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Gene expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Wiskott-Aldrich syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Wiskott-Aldrich syndrome

Most Recent Events

  • 05 Dec 2015 Interim adverse events data from a phase I/II trial in Wiskott-Aldrich Syndrome reported by San Raffaele Telethon Institute for Gene Therapy
  • 29 Jul 2015 Phase-II clinical trials in Wiskott-Aldrich syndrome (In adolescents, In children, In infants, In adults) in Italy (IV)
  • 01 Mar 2015 GlaxoSmithKline, Fondazione Telethon and Ospedale San Raffaele complete enrolment in phase I/II trial for Wiskott Aldrich syndrome (In infants, In children, In adolescents, In adults) in Italy (NCT01515462)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top